Eli Lilly and Company (NYSE:LLY) was a part of 100 hedge fund portfolios at the end of Q2 2024, down from 109 in the previous ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 607.25% and ...

In a sweeping new lawsuit, over 900 people are claiming that Ozempic and other GLP-1 drugs caused them long-term ...

Nationally, the average cost of employer-sponsored health plans is expected to grow 9% next year if companies don’t find ways ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

A growing number of people with type 1 diabetes are becoming overweight or obese, in part because insulin can cause weight ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...

Eli Lilly (LLY) stock gained as Citi resumed its covderage with a buy rating and $1,060 price target, citing optimism for its ...

Eli Lilly is investing $1.8 billion across two manufacturing sites in Ireland to boost production of its hugely popular ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Unrestricted funds (educational activities): Abbott, Dexcom, Eli Lilly, Medtronic, Merck ... help to limit the many complications to which they give rise. A drug such as Mounjaro is as effective at ...

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also ...